Arena Pharmaceuticals Inc. (ARNA)

51.22
1.36 2.59
NASDAQ : Health Technology
Prev Close 52.58
Open 52.58
Day Low/High 51.10 / 52.69
52 Wk Low/High 31.97 / 64.48
Volume 325.77K
Avg Volume 464.70K
Exchange NASDAQ
Shares Outstanding 49.83M
Market Cap 2.62B
EPS -0.60
P/E Ratio 4.30
Div & Yield N.A. (N.A)
4 Big Stocks Getting Big Attention

4 Big Stocks Getting Big Attention

Here's how to trade some of the most active stocks on the market today.

Arena CEO Dumps Stock as Share Price, Investor Confidence Slide

Arena CEO Dumps Stock as Share Price, Investor Confidence Slide

Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.

Insider Trading Alert - SFLY, ARNA And ENS Traded By Insiders

Insider Trading Alert - SFLY, ARNA And ENS Traded By Insiders

Stocks with insider trader activity include SFLY, ARNA and ENS

EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel

EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel

EnteroMedics and its VBLOC "fat-zapping" implantable medical device will be the focus of an FDA advisory panel meeting next Tuesday, June 17. If FDA follows historical form, the agency's review of VBLOC's safety and efficacy will be available publicly tomorrow morning.

'Fast Money' Recap: Reacting to Today's Headlines

'Fast Money' Recap: Reacting to Today's Headlines

The trading panel discussed whether a market pullback is in the card anytime soon.

FDA Delays Decision on Orexigen Obesity Pill by 3 Months

FDA Delays Decision on Orexigen Obesity Pill by 3 Months

FDA needs more time to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of heart-safety related outcomes for Contrave, Orexigen said

Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday

Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday

Selling weight-loss pills to fat Americans is clearly more difficult than Vivus and Arena envisioned. Orexigen will face the same challenges, but of the three companies, it has the best marketing partner in Takeda because of its metabolic drug expertise.

Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition

Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition

I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail means for biotech investor sentiment, but I'll leave the interpretations up to you.

The Expected Rise and Inevitable Fall of MannKind

The Expected Rise and Inevitable Fall of MannKind

Using Arena Pharmaceuticals (a very similar, retail-driven cult stock) as a precedent, MannKind should go even higher as we get closer to July 15, but if/when Afrezza is approved, the sell off begins.

Two pharmaceutical stocks demonstrate portfolio pitfalls and rewards

Two pharmaceutical stocks demonstrate portfolio pitfalls and rewards

By Chris Lau for Kapitall. Obesity is a medical problem that now has drug treatment options. Prior to FDA approval, [...]

ARNA July 11th Options Begin Trading

ARNA July 11th Options Begin Trading

Investors in Arena Pharmaceuticals Inc saw new options become available today, for the July 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new July 11th contracts and identified one put and one call contract of particular interest.

The Seven Deadly Sins of Biotech Investing

The Seven Deadly Sins of Biotech Investing

A fool and is money are soon parted, the old idiom goes. I'll add this: The money parting often happens faster to fools who invest in sketchy small-cap biotech stocks.

The Stupid and Financially Reckless Argument for Eisai Buying Arena Pharma

The Stupid and Financially Reckless Argument for Eisai Buying Arena Pharma

Japanese companies have a history of paying grossly inflated prices for U.S. assets, but the drug maker Eisai would have to be monumentally stupid -- and financially reckless -- to buy out its obesity drug partner Arena Pharmaceuticals.

A View on Ariad Pharma's Bloated Valuation

A View on Ariad Pharma's Bloated Valuation

Even at $86 million in 2014 Iclusig sales, Ariad trades at a lofty and unjustified 13 times enterprise value. For comparison's sake, Medivation's EV/sales multiple is 9 -- and that's only counting U.S. sales of its growing prostate cancer drug Xtandi.

Arena Pharma Denied Request Added Market Exclusivity for Weight-Loss Drug

Arena Pharma Denied Request Added Market Exclusivity for Weight-Loss Drug

Citizen Petition filed by Arena's partner Easai is denied by FDA.

'Mad Money' Lightning Round: Delta Is Flying to $40

'Mad Money' Lightning Round: Delta Is Flying to $40

Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.

Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street

Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street

That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.

Interesting ARNA Put And Call Options For May 2nd

Interesting ARNA Put And Call Options For May 2nd

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the May 2nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new May 2nd contracts and identified one put and one call contract of particular interest.

ARNA April 25th Options Begin Trading

ARNA April 25th Options Begin Trading

Investors in Arena Pharmaceuticals Inc saw new options become available today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new April 25th contracts and identified one put and one call contract of particular interest.

First Week of ARNA October 18th Options Trading

First Week of ARNA October 18th Options Trading

Investors in Arena Pharmaceuticals Inc saw new options begin trading this week, for the October 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

The 10 Most Heavily Shorted Bio-Pharma Stocks

The 10 Most Heavily Shorted Bio-Pharma Stocks

The No. 1 stock on this list has more than half its float short.

Interesting ARNA Put And Call Options For April 4th

Interesting ARNA Put And Call Options For April 4th

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new April 4th contracts and identified one put and one call contract of particular interest.

Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta

Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Interesting ARNA Put And Call Options For March 14th

Interesting ARNA Put And Call Options For March 14th

Investors in Arena Pharmaceuticals Inc saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new March 14th contracts and identified one put and one call contract of particular interest.

Galena, Free Fentanyl Samples and the 'Zombie Apocalypse'

Galena, Free Fentanyl Samples and the 'Zombie Apocalypse'

Fund manager and blogger John Hempton calls out Galena Biopharma for giving away free samples of the potentially deadly fentanyl painkiller Abstral.

Daily Patterns Have Gone Haywire

Gaps and traps are making entry and exit strategies unreliable. Yet it is not a bad time for a little long-side exposure.

Catalent leads parade of drugmakers headed to market

Catalent leads parade of drugmakers headed to market

Nearly two dozen healthcare companies, mostly biotechs, are expected to price in the next few weeks.

Interesting ARNA Put And Call Options For February 28th

Interesting ARNA Put And Call Options For February 28th

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the February 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new February 28th contracts and identified one put and one call contract of particular interest.

Russell 2000 Remains January's Leader

But a lack of momentum, despite breakouts by the Russell and Nasdaq 100, could turn ominous and leave new long positions to face considerable risk.

J.P. Morgan Healthcare Confab Live Blog: Day One

J.P. Morgan Healthcare Confab Live Blog: Day One

TheStreet's Adam Feuerstein is providing live coverage all week from the biotech sector's most important investor conference.

TheStreet Quant Rating: C+ (Hold)